Male Lower Urinary Tract symptoms (LUTs) and Benign Prostatic Hyperplasia (BPH) provide a significant proportion of the core urologists workload, and will continue to do so for the foreseeable future with an increasingly elderly population. This review sets out to provide an overview of the current understanding around BPH and male LUTs as well as investigations and treatment options.
National Institute for Health and Clinical Excellence. The management of lower urinary tract symptoms in men. (Clinical Guideline 127), http://guidance.nice.org.uk/CG97 (2010, accessed June 2011).
6.
McNealJ. Origin and evolution of benign prostatic enlargement. Invest Urol1978; 15: 340–345.
7.
McNealJ. Pathology of benign prostatic hyperplasia: Insight into etiology. Urol Clin North Am1990; 17: 477–486.
8.
BartschGMullerHOberholzerM. Light microscopic and stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol1979; 122: 487–491.
ShapiroEHartantoVLeporH. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate1992; 21: 297–307.
11.
MironeVImbimboCLongoN. The detrusor muscle: An innocent victim of bladder outlet obstruction. Eur Urol2007; 51: 57–66.
12.
HaldT. Urodynamics in benign prostatic hyperplasia: a survey. Prostate suppl.1989; 2: 69–77.
13.
BatesCPWhitesideCGTurner-WarwickR. Synchronus cine-pressure-flow-cystourethrography with special reference to stress and urge incontinence. Br J Urol1970; 42: 714–723.
14.
RosenRAltweinJBoyleP. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol2003; 44: 637–649.
15.
BertacciniAVassalloFMartinoF. Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol2001; 40 (Suppl 1): 13–18.
16.
BarendrechhtMMAbramsPSchumacherH. Do alpha-1 adrenoreceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?Neurourol Urodyn2008; 27: 226–230.
17.
AbramsPH. Prostatism and prostatectomy: The value of urine flow rate measurement in the preoperative assessment for operation. J Urol1977; 117: 70–71.
18.
CrawfordEDMcEwanPPooleCD. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. BJU Int2006; 97: 1267–1272.
19.
MadersbacherSAlivizatosGNordlingJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH guidelines). Eur Urol2004; 46: 547–554.
20.
LimCSAbramsP. The Abrams-Griffin nomogram. World J Urol1995; 153: 1516–1519.
21.
OelkeMAlivizatosMEmbertonM. Guidelines on benign prostatic hyperplasia 2005. In: European Association of Urology Pocket Guideline 2011 Edition. Arnhem: Drukkerij Gelderland bv, 2011: pp.121–128.
22.
RhodesTGirmanCJJacobsenSJ. Longitudinal prostate growth rates during 5 years in randomly selected community men 40–79 years old. J Urol1999; 161: 1174–1179.
23.
JacobsenSJGirmanCJGuessHA. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol1996; 155: 595–600.
24.
WassonJHRedaDJBruskewitzRC. Comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med1995; 332: 75–79.
25.
McConnellJDBarryMJBruskewitzR. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, Number 8, Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
26.
GrosseH. Frequency, localization and associated disorders in urinary calculi. Analysis of 1671 autopsies in urolithiasis. Z Urol Nephrol1990; 83: 469–474.
27.
HunterDJBerra-UnamunoAMartin-GordoA. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. Urol1996; 155: 1965–1970.
28.
MebustWKHoltgreweHLCockettAT. Transurethral prostatectomy: Immediate and postoperative complications. A co-operative study of 13 participating institutions evaluating 3885 patients. J Urol1989; 141: 243–247.
29.
McConnellJRoehrbornCBautistaOM. The long-term effects of doxazosin, finasteride and the combination on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2385–2396.
30.
JacobsenSJJacobsonDJGirmanCJ. Natural history of prostatism: Risk factors for acute urinary retention. J Urol1997; 158: 481–487.
31.
KortmannBBFloratosDLKiemeneyLA. Urodynamic effects of alpha-adrenoreceptor blockers: A review of clinical trials. Urology2003; 62: 1–9.
32.
DjavanBChappleCMilaniS. State of the art on the efficacy and tolerability of alpha-1 adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology2004; 64: 1081–1088.
NickelJCGillingPTammelaTL. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU Int2011; 108: 388–394.
35.
McConnellJDBruskewitzRWalshPC. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia (PLESS). N Engl J Med1998; 338: 557–563.
LeporHWillifordWOBarryMJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med1996; 335: 533–539.
38.
KirbyRSRoerbornCBoyleP. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61: 119–126.
39.
KaplanSAMcConnellJDRoehrbornCG. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol2006; 175: 217–220.
40.
RoehrbornCGSiamiPBarkinJ. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol2010; 57: 123–131.
41.
KaplanSARoehrbornCGRovnerES. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A randomised controlled trial. JAMA2006; 296: 2319–2328.
42.
MaruyamaOKawachiYHanazawaK. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. Int J Urol2006; 13: 1280–1285.
43.
WiltJWIshaniStarkG. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA1998; 280: 1604–1608.
44.
ChappleC. Intraprostatic Injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Eur Urol2011; 59: 755–756.
45.
MadersbacherSMarbergerM. Is transurethral resection of the prostate still justified?BJU Int1999; 83: 227–237.
46.
RoosNPWennbergJEMalenkaDJ. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med1989; 320: 1120–1124.
47.
RassweilerJTeberDKuntzR. Complications of transurethral resection of the prostate (TURP) — incidence, management, and prevention. Eur Urol2006; 50: 969–980.
